Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 17;138(2):178–189. doi: 10.1182/blood.2020009345

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — Effect of 5C12 anti-FXII antibody treatment on the activation of coagulation and coagulopathy in baboons challenged with a lethal dose of HI-SA (LDSA). Time course dynamics of aPTT (A), PT (B), complexes of FXIIa- AT (C), FXIIa-C1 inhibitor (D), kallikrein-AT (E), kallikrein-C1 inhibitor (F), total kininogen (G), cleaved kininogen (H), FXIa-AT (I), FIXa-AT (J), FVIIa-AT (K), FXa-AT (L), TAT (M), and TF mRNA in leukocytes (N) in HI-SA–challenged animals, with or without 5C12 antibody treatment. Same time points are compared between the treated and untreated baboons by using the generalized least squares (gls) function as described in the Statistical analysis section. *P < .05; **P < .01; ***P < .001. The overall P value (pvl) describing the difference between the 2 curves is shown on each graph. P < .05 is considered significant.